153 sm-edtmp
Bone Metastases
M.D. Anderson Cancer CenterradiopharmaceuticalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
34 Active assets in the Bone Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Denosumab Kelly Fitzgerald, MD | Phase 4 | BBB |
Zoledronate Kelly Fitzgerald, MD | Phase 4 | BBB |
Ibandronate Kelly Fitzgerald, MD | Phase 4 | BBB |
RADIUM RA-223 University of California, San Francisco | Phase 3 | BB |
Zometa Sun Yat-sen University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
153 sm-edtmp is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →